Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

Conditions are getting a bit more challenging for the drugmaker.

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

The company, headquartered in the key swing state of Pennsylvania, has announced the creation of 330 jobs in a significant ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... as well as in research and development (R&D), not to mention more investment in manufacturing capacity and perhaps commercial infrastructure.

The reactions to Donald's Trump's victory across the crypto, currency, and stock markets. Super Micro's woes, and the outlook for a company with no auditor, no annual report and, perhaps soon, no ...

Dave Ricks became CEO of Eli Lilly in 2017, but has been working at different departments within the company since 1996. The ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...